First-in-class drug for heart failure best in severe disease: study
Fewer than 12 patients with very low ejection fraction need to be treated to prevent an event including death, investigator says
Patients with the most severely reduced ejection fraction stand to benefit most from the novel heart-failure drug, omecamtiv mecarbil, new analysis of trial data shows.
The findings were presented at ACC.21, the virtual meeting of the American College of Cardiology and simultaneously published in the college’s journal.
Omecamtiv mecarbil is an experimental, first-in-class, selective cardiac-myosin activator that improves cardiac structure and function in patients with heart failure and reduced ejection fraction (HFrEF).
The GALACTIC-HF trial enrolled 8256 patients with symptomatic chronic HF and an ejection fraction of 35% or less.
